Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
NCT05948072
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
250
Enrollment
OTHER
Sponsor class
Conditions
Colorectal Cancer
Liver Metastases
Interventions
DRUG:
mFOLFOX6 + Cetuximab
DRUG:
mFOLFOX 6
Sponsor
Fudan University